DMXAA (Vadimezan) , ≥98% , 117570-53-3
Synonym(s):
5,6-Dimethylxanthenone-4-acetic Acid;ASA404;Vadimezan
| Pack Size | Price | Stock | Quantity |
| 5mg | RMB31.20 | In Stock |
|
| 25mg | RMB119.20 | In Stock |
|
| 100mg | RMB255.20 | In Stock |
|
| 250mg | RMB503.20 | In Stock |
|
| 1g | RMB1599.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 259-261 °C |
| Boiling point: | 520.9±50.0 °C(Predicted) |
| Density | 1.321±0.06 g/cm3(Predicted) |
| vapor pressure | 0Pa at 20℃ |
| storage temp. | 2-8°C |
| solubility | DMSO: 17 mg/mL, soluble |
| form | solid |
| pka | 4.21±0.10(Predicted) |
| color | light brown |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20°C for up to 3 months. |
Description and Uses
DMXAA (117570-53-3) is a STING (Stimulator of Interferon Genes) agonist selective for mouse STING.1,2 Intratumoral administration of DMXAA resulted in tumor regression and complete rejection in mouse xenografts.3 Tumor regression induced by DMXAA results from a cascade of cellular events which include disruption of tumor vasculature followed by the release of chemokines which trigger the recruitment of immune cells.4 DMXAA induced expression of IFN-β resulting in a striking expansion of leukemia-specific T cells extending survival in two acute myeloid leukemia models.5
Vadimezan is a drug that displayed vascular-disrupting activity and induced haemorrhagic necrosis and tumour regression in pre-clinical animal models. It is a substrate for the immune adaptor protein STING in mice.
Safety
| Symbol(GHS) |   GHS07,GHS09 |
| Signal word | Warning |
| Hazard statements | H302-H400 |
| Precautionary statements | P273-P301+P312+P330 |
| Hazard Codes | Xn,N |
| Risk Statements | 22-50/53 |
| Safety Statements | 60-61 |
| RIDADR | UN 3077 9/PG 3 |
| WGK Germany | 3 |
| RTECS | ZD5536200 |
| HS Code | 2932.99.7000 |
